Trial Profile
Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 09 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2005 New trial record.